NCT04116476View on ClinicalTrials.gov

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

February 16, 2021

Study Completion Date

February 16, 2021

Conditions
Mild and Moderate Hepatic Impairment
Interventions
DRUG

MT-7117

Single Dose of MT-7117

Trial Locations (1)

33136

University of Miami Clinical Pharmacology Unit, Miami

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma America Inc.

INDUSTRY